Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations

Blaszczak, Alecia; Trinidad, John; Cartron, Alexander M

doi:10.1016/j.jaad.2020.04.030

Cited by 18 publications

(21 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is no clinical evidence nor any registered clinical trials assessing the possibility of IL-18 blockers and IL-33 blockers in COVID-19. TNF-a and IFN-g are also key inflammatory cytokines and attractive targets in the control of cytokine storms (6,90,91), and clinical trials are ongoing to test these blockers in COVID-19 (ChiCTR2000030089, NCT04324021) (70,92). JAK/STAT (janus kinase/signal transducers and activators of transcription) signal transduction pathway, a common downstream signaling pathway of various cytokines, can block multiple targeted cytokines at the same time if inhibited (93,94).…”

Section: Other Blockersmentioning

confidence: 99%

Controlling Cytokine Storm Is Vital in COVID-19

et al. 2020

View full text Add to dashboard Cite

Corona virus disease 2019 (COVID-19) has caused a global outbreak and severely posed threat to people’s health and social stability. Mounting evidence suggests that immunopathological changes, including diminished lymphocytes and elevated cytokines, are important drivers of disease progression and death in coronavirus infections. Cytokine storm not only limits further spread of virus in the body but also induces secondary tissue damage through the secretion of large amounts of active mediators and inflammatory factors. It has been determined that cytokine storm is a major cause of deaths in COVID-19; therefore, in order to reverse the deterioration of severe and critically ill patients from this disease, the cytokine storm has become a key therapeutic target. Although specific mechanisms of the occurrences of cytokine storms in COVID-19 have not been fully illuminated, hyper-activated innate immune responses, and dysregulation of ACE2 (angiotensin converting enzyme 2) expression and its downstream pathways might provide possibilities. Tailored immunoregulatory therapies have been applied to counteract cytokine storms, such as inhibition of cytokines, corticosteroids, blood purification therapy, and mesenchymal stem cell therapy. This review will summarize advances in the research of cytokine storms induced by COVID-19, as well as potential intervention strategies to control cytokine storms.

show abstract

Section: Other Blockersmentioning

confidence: 99%

Controlling Cytokine Storm Is Vital in COVID-19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, Blaszczak concluded that it was difficult to extrapolate these data to SARS-CoV-2 infection. Nonetheless, these data may be useful to clinicians for making informed treatment decisions for patients with HS during the ongoing COVID-19 pandemic 39 . Adalimumab is the only currently FDA-approved systemic medication for the treatment of HS.…”

Section: Treatment Optionsmentioning

confidence: 99%

The most recent advances in understanding and managing hidradenitis suppurativa

2020

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicle unit that typically develops after puberty. HS has a significant negative impact on both the quality of life (QOL) of patients affected by this disease as well as family members and caregivers. However, the pathogenesis of HS is multifactorial and still remains to be fully elucidated, which makes the development of treatments difficult. The last 10 years have seen a surge in HS research, and many new findings have come to light, yet much more remains to be elucidated. Physicians must employ a multidisciplinary approach to maximally address all facets of HS. Clinical characteristics of the disease that differ between females and males as well as across different races and ethnic groups must be considered. Targeted topical, oral, and injectable therapies continue to be developed for HS as a greater understanding of the pathogenesis is reached. However, randomized controlled trials regarding dietary factors that may contribute to HS are needed to meet our patients’ growing concerns and questions about the role of diet in HS pathogenesis. Finally, improved outcome measures are needed to standardize HS severity and grading between physicians and clinical trials, and a more diverse representation of HS populations is needed in clinical trials.

show abstract

“…In any case, following the evidence available to date, the current recommendation would be not to withdraw the biologic treatment in patients with HS who present with symptoms of COVID-19 as in other immune-mediated skin pathologies such as psoriasis. [3][4][5] We are aware of the limitations of this study, including the small sample size, the absence of statistical analysis, and the lack of serologies or molecular research to confirm the diagnosis of COVID-19 infection. However, the main interest of this work is that in a population area of the southeast of Madrid very widely affected by the pandemic (with 2176 confirmed severe cases during this period), we observe that there have not been any severe cases within a series of 75 patients with HS, even when these pathologies share risk factors, regardless of the treatment they receive.…”

Section: Experience In Patients With Hidradenitis Suppurativa and Covmentioning

confidence: 99%

Experience in patients with hidradenitis suppurativa and COVID-19 symptoms

Galán

Silvente

González

et al. 2020

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

show abstract

Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations

Cited by 18 publications

References 2 publications

Controlling Cytokine Storm Is Vital in COVID-19

Controlling Cytokine Storm Is Vital in COVID-19

The most recent advances in understanding and managing hidradenitis suppurativa

Experience in patients with hidradenitis suppurativa and COVID-19 symptoms

Contact Info

Product

Resources

About